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How to treat hypercholesterolaemia
David Colquhoun, Cardiologist, Wesley Medical Centre, and Greenslopes Private 
Hospital, Brisbane
Summary 
An elevated low density lipoprotein cholesterol 
is a major cause of atherosclerosis. Reducing 
the concentration of this lipoprotein stabilises 
atherosclerotic plaques, and may lead to 
regression of the atherosclerosis. A moderate 
reduction of the plasma concentration of this 
lipoprotein significantly decreases recurrent 
coronary events. Therapy is a combination of 
lifestyle modification, nutraceuticals and drug 
treatment. The most convenient and effective 
drugs are the HmGCoA reductase inhibitors or 
'statins'. They control hyperlipidaemia and help 
to prevent myocardial infarction, unstable angina, 
sudden death and stroke. 
Key words: antilipidaemic drugs, cholesterol, coronary disease, 
diet, dietary supplements. 
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Introduction
Hypercholesterolaemia is a major risk factor along with 
smoking, hypertension and diabetes for developing 
atherosclerosis. Coronary heart disease is almost entirely due 
to atherosclerosis in the coronary arteries. Atherosclerosis in 
the carotid arteries also plays a major role in stroke. Rupture 
of an atheromatous plaque in the coronary arteries is the 
pathological event underlying the acute coronary syndromes of 
sudden death, acute myocardial infarction and unstable angina. 
Plaques that rupture are generally rich in cholesterol and the 
risk of coronary events is proportional to the serum cholesterol 
concentration, specifically low density lipoprotein cholesterol.
lipoproteins
The serum lipids are cholesterol and triglycerides. They 
are transported in the blood as large molecules known as 
lipoproteins. In addition to protein (apoproteins), cholesterol, 
cholesteryl esters and triglycerides, the lipoproteins also carry 
antioxidants such as vitamin E, dietary polyphenols and  
co-enzyme Q10. There are five major classes of lipoprotein  
(Table 1). Intermediate density lipoprotein and low density 
lipoprotein (LDL) are the most atherogenic, while high density 
lipoprotein (HDL) is anti-atherogenic.
When triglycerides are elevated, this is usually associated  
with an elevation of very low density lipoprotein cholesterol 
(VLDL cholesterol). This lipoprotein has a triglyceride:cholesterol 
ratio of 2:1. When fasting triglyceride levels are greater than  
1.5 mmol/L, the risk of coronary heart disease and stroke 
increases significantly. Fasting triglyceride levels greater than  
1.9 mmol/L, compared to less than 1.5 mmol/L, increase the risk 
of coronary heart disease and stroke by more than 30%.
When there is an elevated serum cholesterol it is almost always 
due to an elevation of the LDL cholesterol. Occasionally an 
elevated cholesterol is due to a high concentration of HDL 
cholesterol, but these patients are not at increased risk of 
cardiovascular disease. As LDL cholesterol accounts for 60–70% 
of the total cholesterol and is atherogenic, it is the target of 
treatment in patients with hypercholesterolaemia.
Target concentrations
Patients must be assessed for other risk factors, the presence 
of cardiovascular disease and other causes of raised cholesterol 
to determine their absolute risk of a coronary event.1 An 
appropriate target can then be set for their LDL cholesterol 
concentration.
A meta-analysis of randomised trials of statins showed that for 
each 1 mmol/L reduction of LDL cholesterol (which generally 
equates to a 20% reduction of LDL cholesterol) there is a  
20–30% relative risk reduction of coronary heart disease events.2 
Lowering the LDL a further 30% or so, or an extra 1 mmol/L, 
reduces coronary heart disease events by a further 20–30%. 
The target for an asymptomatic individual who has a low risk  
of developing coronary heart disease is an LDL cholesterol of 
Table 1
lipoproteins
Chylomicrons
Triglyceride rich
Atherogenic
Very low density 
lipoprotein
Intermediate density 
lipoprotein
Low density lipoprotein
Cholesterol rich
High density lipoprotein Anti-atherogenic
Intermediate and low density lipoprotein contain the highest 
proportion of cholesterol while chylomicrons contain little 
cholesterol.
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less than 4 mmol/L with triglycerides less than 2 mmol/L,  
HDL greater than 1 mmol/L and a total cholesterol less than 
5.5 mmol/L. For a patient who has already developed coronary 
heart disease there is the lower target of an LDL cholesterol 
less than 2.5 mmol/L. Patients with established coronary heart 
disease and a very high risk of a future cardiovascular event 
should have a target of less than 2 mmol/L. These targets 
broadly reflect recommendations by the Australian National 
Heart Foundation3 and the American Heart Association 
guidelines.4 Reducing LDL cholesterol to below appropriate 
targets is more important than the method or specific drug used 
to achieve the reduction.5
Diet
Lifestyle factors, particularly a diet rich in saturated fats and 
low in fibre, play a significant role in the elevation of LDL 
cholesterol. A key element of the first dietary guidelines 
to prevent coronary heart disease was to lower foods rich 
in saturated fat. Subsequent international guidelines have 
continued to focus on lowering foods rich in saturated fat. 
Replacing saturated fat with either carbohydrate or foods rich in 
mono- or polyunsaturated fats and high fibre foods is effective 
in lowering LDL cholesterol. All of these independently lower 
LDL cholesterol. Avoid baked foods containing trans fatty acids, 
such as pies, pastries, cakes and biscuits. An individual patient's 
response to diet can vary considerably and is usually seen in 
4−6 weeks. Some patients are very responsive and can have up 
to 30% lowering of LDL cholesterol. 
Traditional cuisines which are associated with low LDL 
cholesterol and low rates of heart disease are Mediterranean-
type diets, as found in Greece, Italy and Spain, and cuisine low 
in total fat such as in Japan. It is also clear that a high intake 
of fish, particularly fish rich in marine omega-3 fatty acids, is 
associated with a low risk of heart attack and stroke. 
After a myocardial infarction, a Mediterranean-type diet 
compared to a usual low fat diet is associated with a 50% 
relative reduction in mortality. This is independent of any change 
in serum cholesterol (see box).6
Weight loss
Weight loss can favourably influence lipids irrespective of how 
it is achieved. For every kilogram decrease in body weight, LDL 
cholesterol decreases by 0.02 mmol/L, triglycerides decrease by 
0.015 mmol/L and HDL cholesterol increases by 0.14 mmol/L.7 
Unfortunately, significant weight loss is difficult to achieve 
and maintain, but losing 5–10 kg is achievable and can make a 
difference to the risk profile. 
exercise
Most exercise studies have indicated that regular aerobic 
exercise improves the lipid profile independent of diet and 
drugs. Regular exercise decreases LDL cholesterol by 10% and 
increases HDL cholesterol by 5%.8 There is a dose response 
between the amount of exercise and lipoprotein changes. 
Moderate aerobic exercise is defined usually as moderate effort 
of half an hour of intentional exercise most days of the week. 
Nutraceuticals
The nutraceuticals that can help to lower LDL cholesterol are plant 
sterols/stanols and soluble fibre. In Australia, the foods which can 
be enriched with plant sterols are margarine, milk and yoghurt. A 
dose of 2–4 g of plant sterols is needed, which equates to at least 
four teaspoons of plant-enriched margarine per day. A 200 g tub of 
enriched yoghurt only provides the equivalent of one teaspoon so 
is not that helpful for achieving targets.
On average plant sterols reduce LDL cholesterol by 10%, but 
this may vary from 0 to 30%. They have an additive effect to 
drug therapy.
A tablespoon or two of soluble fibre, such as psyllium, lowers 
LDL cholesterol by approximately 5%. Garlic and policosanol 
have been found to have negligible effects in most recent 
studies. Omega-3 fatty acids from fish oil are effective in 
lowering triglycerides, but have no effect in lowering LDL 
cholesterol at usual therapeutic doses. Very high doses of fish  
oil may in fact increase LDL cholesterol.
Drug therapy
If diet and nutraceuticals do not adequately reduce the 
LDL cholesterol and the patient remains at high risk of a 
cardiovascular event, drug therapy is indicated. HMGCoA 
reductase inhibitors, 'statins', are the first drugs to use. They 
are extremely efficacious and more than 90% of patients can 
tolerate them with negligible or no adverse effects. All statins 
have non-lipid lowering properties such as antiplatelet effects. 
However, most, if not all, the cardiovascular benefit can be 
accounted for by the improved lipoprotein profile, mainly by 
lowering LDL cholesterol.
mediterranean diet after myocardial infarction 6
The healthy Mediterranean-type diet initially referred to 
the food traditionally eaten by the people of Naples. It was 
vegetarian-like, high in nuts and olive oil, vegetables and 
pasta which was cooked al dente. Fruit was eaten frequently 
along with some cheese, wine and nuts. The Mediterranean 
diet later extended to include the traditional diets of Crete 
and Spain. 
The Lyon Diet Heart Study involved just over 600 individuals 
who had survived a myocardial infarction. After 3.5 years the 
trial was stopped early as there was a clear benefit for patients 
on the Mediterranean-type diet compared to a low fat diet. 
The benefit was independent of drug therapy and serum 
cholesterol. 
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Efficacy of statins
Statins differ in efficacy, with the earlier statins lowering LDL 
to a similar extent to bile resins such as cholestyramine and 
nicotinic acid. The newer statins, atorvastatin and rosuvastatin, 
are considerably more efficacious in lowering LDL cholesterol, 
but there is little evidence as yet that this further improves long-
term clinical outcomes. High dose simvastatin and controlled-
release fluvastatin are of intermediate efficacy. The highest 
doses of the most efficacious statins can achieve a 2 mmol/L 
reduction (which is up to a 60% lowering of LDL from baseline). 
A number of recent trials have compared moderate to vigorous 
LDL lowering, and there is the expected predictable greater 
benefit of cardiovascular disease prevention.
Most of the effect of the statins occurs at less than the 
maximum dose. If the patient's target cholesterol is not reached, 
adding another drug may therefore have more effect than 
increasing the statin dose.
Adverse effects of statins
If adverse effects occur, more than 90% appear within the first 
three months. Adverse effects tend to be dose related and are 
similar between statins. If a patient has adverse effects from one 
statin, the dose can be lowered, given in divided doses or every 
second day. Alternatively, the patient can be switched to another 
statin or a controlled-release formulation. 
The common adverse effects are musculoskeletal aches. 
Occasionally there is an associated increase in creatine kinase 
and rarely (less than 1/1000) a true myositis can occur. There is 
increased risk of myositis in those with renal failure, diabetes and 
in the elderly. If the creatine kinase is greater than 300 IU/mL, 
consider stopping the statin and repeat the test one week later.
A rise in the liver transaminases can occur so liver function tests 
are recommended before and during treatment. True hepatitis is 
extremely rare. Measure liver function every six months and if 
the transaminases are greater than twice the upper limit, stop the 
statin and repeat the liver function test in 3–4 weeks. Depending 
on the results, restart at the same dose, for example, if the 
patient's transaminase levels were only just above the cut-off 
point and then normalised after stopping the statin. Otherwise, 
restart the patient on half the dose and retest their liver function 
in 3–4 weeks. Many patients have a mild transient elevation of 
liver enzymes which is of no consequence. Persistent elevation 
of liver enzymes that are in the moderate range (up to 2–3 times 
above the upper limit of normal) may relate to the presence of 
fatty liver disease rather than drug therapy.
Long-term follow-up of patients in trials has not shown an 
increase in the risk of cancer from long-term exposure to statins.
Other drugs
In approximately 75% of the patients who cannot tolerate 
even half the usual dose of statins, ezetimibe can be effective. 
Ezetimibe inhibits the absorption of dietary cholesterol. The 
dose of ezetimibe is 10 mg per day and there is no value in 
going higher. Ezetimibe lowers LDL by approximately 15%. 
Some individuals develop aches and pains on the usual dose 
of ezetimibe (10 mg/day). Reducing the dose to 10 mg once 
per week still produces some lowering of LDL cholesterol 
but without the adverse effects. Ezetimibe can further reduce 
LDL cholesterol in patients on maximum doses of statins. 
Adding ezetimibe 10 mg per day can often lead to a synergistic 
lowering of LDL cholesterol by an extra 20–25%. Patients who 
are very sensitive to statin adverse effects can be stabilised 
on ezetimibe, then given a mini dose of a statin, such as 
rosuvastatin 2.5 mg every second or third day, with significant 
benefit. However, there is no current evidence that ezetimibe 
reduces the risk of heart attack or stroke, either alone or in 
combination with statins.
After statins and ezetimibe, other drugs to consider are bile 
resins (for example cholestyramine), fenofibrate and nicotinic 
acid (niacin, vitamin B3). More than 50% of patients cannot 
tolerate more than 4 g of cholestyramine per day, and it is best 
mixed with juice. One sachet per day is expected to lower the 
LDL cholesterol by around 10% and it has an additive effect with 
statin therapy. Fenofibrate 145 g per day lowers LDL cholesterol 
by around 10%, but its major role is to lower triglycerides. 
Nicotinic acid at a dose of 3 g per day lowers LDL cholesterol by 
about 20%, but more than 75% of patients cannot tolerate even 
half this dose due to severe flushing. Gemfibrozil has no effect 
on lowering LDL cholesterol. 
Treatment of hypertriglyceridaemia
First-line treatment for elevated triglycerides (VLDL cholesterol) 
consists of a diet rich in mono- and polyunsaturated fat and low 
glycaemic index carbohydrate food, caloric restriction (leading 
to weight reduction) and exercise. The next step is consideration 
of marine omega-3 fatty acids (fish oil) and fibrates.
Conclusion
Elevated LDL cholesterol is a major risk factor for coronary heart 
disease and is the major target of therapy to prevent coronary 
events. In patients with clinical coronary heart disease, lowering 
the LDL cholesterol to less than 2.5 mmol/L lowers the relative 
risk of developing coronary events by approximately 25%, and 
lowering it to below 2 mmol/L reduces the relative risk by 50%. 
Therapy involves diet, regular exercise, nutraceuticals and drug 
treatment along with attention to other risk factors. Statins are 
the first choice of drug therapy. 
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Self-test questions
The following statements are either true or false  
(answers on page 139)
1. Most of the effect of a statin on low density lipoprotein 
cholesterol occurs below the maximum recommended 
dose.
2. Fish oil can significantly reduce concentrations of low 
density lipoprotein cholesterol.
Australian Prescriber books
Abnormal laboratory results, edited by 
Geoffrey Kellerman, covers a wide range 
of commonly ordered laboratory tests 
for health professionals. It also provides 
useful background reading for students. 
The book is based on articles published 
in the ongoing Abnormal laboratory 
results series in Australian Prescriber. 
2nd edition 2006. 302 pages, $46.99.
Pharmacokinetics made easy, edited by 
Donald Birkett, is designed to demystify 
this complex topic for readers who are 
not pharmacologists. It is made up of a 
collection of articles that have appeared 
in Australian Prescriber. 
Revised edition 2002. 132 pages, $28. 
These titles are available to Australian Prescriber readers at 
15% discount from McGraw-Hill Australia. 
Contact customer service by phoning 02 9900 1888 or 
emailing cservice_sydney@mcgraw-hill.com
New blue card
The Therapeutic Goods Administration has introduced a 
new blue card for reporting adverse drug reactions. It can be 
downloaded from www.tga.gov.au/adr/bluecard.htm
For hard copies of the blue card contact the Adverse Drug 
Reactions Unit by email (adrac@tga.gov.au) or phone  
(1800 044 114).
A blue card will be enclosed with the December issue of 
Australian Prescriber.
You can also report an adverse reaction: 
n	 online at www.tga.gov.au/adr/bluecard.htm (click on 
'Report electronically')
n	 by email  adrac@tga.gov.au
n	 by fax  02 6232 8392 
n	 by phone  1800 044 114
Remember, you don't have to be certain, just suspicious! 
